Immunophenotyping for diagnosis and prognosis in MDS: Ready for general application?

Cremers, Eline M.P.; Alhan, Canan; Westers, Theresia M.; Ossenkoppele, Gert J.; Loosdrecht, Arjan A. van de

doi:10.1016/j.beha.2014.11.003

Cited by 10 publications

(6 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the early diagnosis of leukemia for the treatment and the improvement of the quality of life of patients is essential. At present, the commonly used method for detecting leukemia is taking peripheral blood cells and bone marrow, after that many kinds of analysis [ 6 ], including cell morphology, cytochemistry [ 7 – 9 ], immunophenotype [ 10 , 11 ], immunohistochemical [ 12 , 13 ], and aptamer-based flow cytometry [ 14 , 15 ], have been carried out. These methods can detect leukemia cells, but they still have many shortcomings such as high cost, low sensitivity, and being complicated.…”

Section: Introductionmentioning

confidence: 99%

A Graphene Oxide-Based Fluorescent Aptasensor for the Turn-on Detection of CCRF-CEM

et al. 2018

View full text Add to dashboard Cite

A convenient, low-cost, and highly sensitive fluorescent aptasensor for detection of leukemia has been developed based on graphene oxide-aptamer complex (GO-apt). Graphene oxide (GO) can absorb carboxyfluorescein-labeled Sgc8 aptamer (FAM-apt) by π-π stacking and quench the fluorescence through fluorescence resonance energy transfer (FRET). In the absence of Sgc8 target cell CCRF-CEM, the fluorescence is almost all quenched. Conversely, when the CCRF-CEM cells are added, the quenched fluorescence can be recovered rapidly and significantly. Therefore, based on the change of fluorescence signals, we can detect the number of CCRF-CEM cells in a wide range from 1 × 102 to 1 × 107 cells/mL with a limit of detection (LOD) of 10 cells/mL. Therefore, this strategy of graphene oxide-based fluorescent aptasensor may be promising for the detection of cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

A Graphene Oxide-Based Fluorescent Aptasensor for the Turn-on Detection of CCRF-CEM

et al. 2018

View full text Add to dashboard Cite

show abstract

“…23 Furthermore, erythroblast analysis is often useful in MDS; however, it is not included in the Ogata Score. 24 Aberrations were noted in erythroblast CD34, CD36, CD45, CD71 and CD117 expression in MDS. 25,26 Other reports also interestingly found increased Ogata Score sensitivity when adding CD36 and CD71 erythroblast expression.…”

Section: Discussionmentioning

confidence: 99%

Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic syndrome

Pembroke

Joseph

Smith

et al. 2021

Int J Lab Hematology

View full text Add to dashboard Cite

Introduction:The myelodysplastic syndromes (MDSs) are heterogeneous myeloid malignancies, conventionally diagnosed by cytomorphology and cytogenetics, with an emerging role for flow cytometry. This study compared the performance of a 4-parameter flow cytometry scoring system, the Ogata Score, with other modalities in the diagnosis of MDS.Methods: Bone marrow aspirate and trephine biopsies from 238 patients performed to assess for possible MDS were analysed, and the flow cytometry score was retrospectively applied. The sensitivity and specificity of the flow cytometry score, the aspirate microscopy, the trephine microscopy with immunohistochemistry, and cytogenetic and molecular results were determined relative to the final diagnosis. Results:The medical records of the 238 patients were reviewed to determine the final clinical diagnosis made at the time of the bone marrow examination. This final diagnosis of MDS, possible MDS or not MDS, was based on clinical features and laboratory tests, including all parameters of the bone marrow investigation, except for the flow cytometry score, which was only determined for this study. The flow cytometry score was 67.4% sensitive and 93.8% specific. Aspirate microscopy had higher sensitivity (83.7%) and similar specificity (92.0%), whereas trephine microscopy had similar sensitivity (66.3%) and specificity (89.4%) to flow cytometry. Although the flow cytometry score had a lower sensitivity than aspirate microscopy, in 18 patients (7.6% of the total) the flow cytometry score was positive for MDS, whereas aspirate microscopy was negative or inconclusive. Conclusion:The flow cytometry score and trephine microscopy exhibited reasonable sensitivity and high specificity, and complement aspirate microscopy in the assessment of MDS.

show abstract

“…The development of multilaser cytometers, monoclonal antibodies directed toward an increased number of antigens, new fluorochromes and the development of software for data analysis [29] shifted the role of multiparameter flow cytometry (MFC) from being crucial for the diagnosis and classification of hematopoietic neoplasms [30] toward the precision hematology. MFC is now used in hematology not only to delineate or define subtypes of acute leukemia but also to monitor a therapy response by measurable residual disease (MRD) testing [31] and can be further used to refine risk assessments and treatment decisions [32]. It has the capability of identifying and enumerating subpopulations within complex cellular mixtures.…”

Section: Advanced Omics Technologies and Personalized Laboratory Medimentioning

confidence: 99%

Personalized laboratory medicine: a patient-centered future approach

Žitnik

Černe

Mancini

et al. 2018

Clinical Chemistry and Laboratory Medicine (CCLM)

View full text Add to dashboard Cite

In contrast to population-based medical decision making, which emphasizes the use of evidence-based treatment strategies for groups of patients, personalized medicine is based on optimizing treatment at the level of the individual patient. The creation of molecular profiles of individual patients was made possible by the advent of "omics" technologies, based on high throughput instrumental techniques in combination with biostatistics tools and artificial intelligence. The goal of personalized laboratory medicine is to use advanced technologies in the process of preventive, curative or palliative patient management. Personalized medicine does not rely on changes in concentration of a single molecular marker to make a therapeutic decision, but rather on changes of a profile of markers characterizing an individual patient's status, taking into account not only the expected response to treatment of the disease but also the expected response of the patient. Such medical approach promises a more effective diagnostics with more effective and safer treatment, as well as faster recovery and restoration of health and improved cost effectiveness. The laboratory medicine profession is aware of its key role in personalized medicine, but to empower the laboratories, at least an enhancement in cooperation between disciplines within laboratory medicine will be necessary.

show abstract

Immunophenotyping for diagnosis and prognosis in MDS: Ready for general application?

Cited by 10 publications

References 39 publications

A Graphene Oxide-Based Fluorescent Aptasensor for the Turn-on Detection of CCRF-CEM

A Graphene Oxide-Based Fluorescent Aptasensor for the Turn-on Detection of CCRF-CEM

Comparison of flow cytometry with other modalities in the diagnosis of myelodysplastic syndrome

Personalized laboratory medicine: a patient-centered future approach

Contact Info

Product

Resources

About